Rosenow E C
Calif Med. 1952 Jun;76(6):396-401.
The production in 1915 of herpes zoster or "posterior" poliomyelitis in animals with a streptococcus led to further research on the etiologic importance of streptococci in "anterior" poliomyelitis.A specific streptococcus was demonstrated consistently in persons with poliomyelitis and in well persons having contact with them or merely inhabiting an area in which poliomyelitis was epidemic. That the organism was not present in areas remote from contact with the disease was likewise demonstrated.The streptococcus has been isolated from filtrates of poliomyelitis virus and from the tissues and exudates which harbor the virus. It appears in the spinal fluid in the preparalytic stage of poliomyelitis and disappears from the spinal fluid during the severe stage of the disease. Antibody and antigen prepared from the streptococcus were used to determine the presence of antigen and antibody indicative of streptococcal infection in many patients with poliomyelitis and in well persons. The intensity of reaction indicating specific streptococcal antigen was directly proportional to the degree of paralysis in patients; the reaction was greater in persons whose age, sex and previous isolation from the disease would normally indicate greater susceptibility. The test for antibody gave opposite results. Specific agglutinins for the streptococcus and neutralizing antibody for the virus were present consistently in the serum of persons and monkeys during recovery from poliomyelitis. Virus produced in vitro from the associated streptococcus caused all the clinical and pathologic features of poliomyelitis in monkeys inoculated with it, and the animals that recovered from the disease thus induced were proved to be immune thereafter to the natural virus. Antistreptococcic serum prepared in horses was used to treat poliomyelitis. In a group of monkeys inoculated with the virus of the disease, 6 per cent of those receiving the serum before inoculation died of the disease; of the control group, 82 per cent. In a series of poliomyelitis patients treated with the serum the mortality rate was 8 per cent; in a control series, 21 per cent. In a series treated in all stages of the disease by the author, 10 per cent died; of those who did not receive the serum, 25 per cent. An antibody has been prepared from the streptococcus which appears to prevent paralysis and otherwise mitigate poliomyelitis and to provide immunization from the disease.The conclusion is reached that the virus of poliomyelitis is a form of the specific streptococcus, which is the agent in primary infections and in the development of the immunizing antibody.
1915年,用一种链球菌在动物身上引发了带状疱疹或“后”脊髓灰质炎,这促使人们进一步研究链球菌在“前”脊髓灰质炎病因学中的重要性。在脊髓灰质炎患者以及与他们有接触或仅仅居住在脊髓灰质炎流行地区的健康人身上,始终能发现一种特定的链球菌。同样也证实,在远离该病接触区域的地方不存在这种微生物。已经从脊髓灰质炎病毒滤液以及携带该病毒的组织和渗出物中分离出了这种链球菌。它出现在脊髓灰质炎麻痹前期的脑脊液中,在疾病的严重阶段从脑脊液中消失。用这种链球菌制备的抗体和抗原,用于检测许多脊髓灰质炎患者和健康人身上是否存在表明链球菌感染的抗原和抗体。表明特定链球菌抗原的反应强度与患者的麻痹程度成正比;在年龄、性别和以往与该病隔离情况通常表明易感性较高的人群中,反应更强。抗体检测结果则相反。在脊髓灰质炎康复过程中,人和猴子的血清中始终存在针对这种链球菌的特异性凝集素和针对该病毒的中和抗体。由相关链球菌在体外产生的病毒,对接种了它的猴子引发了脊髓灰质炎的所有临床和病理特征,而且从由此诱发的疾病中康复的动物,后来被证明对天然病毒具有免疫力。用马制备的抗链球菌血清用于治疗脊髓灰质炎。在一组接种了该病病毒的猴子中,接种前接受血清治疗的猴子有6%死于该病;对照组的死亡率为82%。在一系列接受血清治疗的脊髓灰质炎患者中,死亡率为8%;在对照组中为21%。在作者对疾病各个阶段进行治疗的一系列病例中,接受治疗的患者死亡率为10%;未接受血清治疗的患者死亡率为25%。已经从这种链球菌中制备出一种抗体,它似乎可以预防麻痹,减轻脊髓灰质炎的其他症状,并提供对该病的免疫保护。得出的结论是,脊髓灰质炎病毒是这种特定链球菌的一种形式,它是原发性感染和免疫抗体形成过程中的病原体。